Efficacy and safety of ixekizumab versus adalimumab in patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomised SPIRIT-H2H trial
Make a Submission
Journal Information:
Editors-in-Chief: Giuseppe Argenziano
Language: English
Frequency: 4 issues/year
eISSN: 2160-9381
Impact Factor 2025: 2.4
CiteScore 2025: 2.2
SJR 2025: 0.504 - SNIP 2025: 0.746
Indexed in: MedLine PubMed (NLM ID 101585990) 1989-ongoing; Scopus coverage years 1989-ongoing; Web of Science Core Collection – ESCI (Emerging Sources Citation Index- Clarivate), Google scholar
2.2
2025CiteScore
48th percentile
Powered by 
DPC is proudly supported by
information links